Journal
NEURO-ONCOLOGY
Volume 25, Issue 3, Pages 433-446Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuonc/noac239
Keywords
glioblastoma; immunomodulation; radiotherapy
Categories
Ask authors/readers for more resources
Cancer treatment for Glioblastoma (GBM) is challenging due to limited survival and high relapse rates. This study explores the potential of immunotherapy targeting in GBM treatment by investigating the immunomodulatory effects of radiotherapy (RT) on tumors. The findings suggest that RT can modify the tumor immunogenicity and highlight the therapeutic potential of immunotherapy in fighting GBM.
Cancer treatment protocols depend on tumor type, localization, grade, and patient. Despite aggressive treatments, median survival of patients with Glioblastoma (GBM), the most common primary brain tumor in adults, does not exceed 18 months, and all patients eventually relapse. Thus, novel therapeutic approaches are urgently needed. Radiotherapy (RT) induces a multitude of alterations within the tumor ecosystem, ultimately modifying the degree of tumor immunogenicity at GBM relapse. The present manuscript reviews the diverse effects of RT radiotherapy on tumors, with a special focus on its immunomodulatory impact to finally discuss how RT could be exploited in GBM treatment through immunotherapy targeting. Indeed, while further experimental and clinical studies are definitively required to successfully translate preclinical results in clinical trials, current studies highlight the therapeutic potential of immunotherapy to uncover novel avenues to fight GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available